GlassScriptPhysician profile
Youssef Hassan
NPI 1649207200
$1,744.28
in general payments reported to CMS, 2019-2025
27 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $91.25 · 2024: $362 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $289.85 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novo Nordisk INC | $275.24 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $268.90 | 2024-2025 | Minimed 780g, Inceptiv |
| Lilly USA, LLC | $120.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $91.25 | 2020 | |
| Amgen INC. | $90.53 | 2019-2025 | Tepezza, Repatha, Evenity |
| Abbvie INC. | $54.38 | 2024-2025 | |
| Dexcom, INC. | $51.96 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $49.20 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $48.99 | 2024-2025 | |
| Horizon Therapeutics Plc | $40.33 | 2019 | |
| Astellas Pharma US INC | $37.88 | 2025 | Veozah |
| Ibsa Pharma INC. | $32.73 | 2024-2025 | Flector, Tirosint, Licart |
| Alexion Pharmaceuticals, INC. | $29.47 | 2025 | Strensiq |
| Rhythm Pharmaceuticals, INC. | $26.75 | 2025 | Imcivree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $26.18 | 2024 | Senza |
| Abbott Laboratories | $24.05 | 2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $22.97 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $22.00 | 2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $20.96 | 2019 | |
| Ascensia Diabetes Care US INC. | $19.28 | 2025 | |
| Tandem Diabetes Care, INC. | $19.28 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $18.10 | 2024 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $17.19 | 2024 | |
| Amarin Pharma, INC. | $17.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.39 | 2019 | |
| Merck Sharp & Dohme LLC | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.